摘要
目的探讨病种基础诊疗模块在疾病诊断相关分组(DRG)为恶性增生性疾病的化学和/或免疫治疗住院病人控费管理中的应用效果。方法调取本院病种基础诊疗模块应用前后,接受化学及/或免疫治疗的恶性增生性疾病职工医保病例资料,其中应用前394例、应用后584例。分析病种基础诊疗模块应用前后病人的住院天数、医疗总费用,以及药费、耗材费、检验费、检查费及其占比的变化。结果使用病种基础诊疗模块控费后,DRG为“恶性增生性疾病的化学及/或免疫治疗”的病人的住院总费用、住院天数、药费、耗材费、药费占比均少于或低于应用前,而检验费占比高于应用前(均P<0.05);病种基础诊疗模块应用前后的检查费、检验费、检查费占比、耗材占比差异均无统计学意义(均P>0.05)。结论使用病种基础诊疗模块进行控费管理可行有效,其有利于规范临床诊疗行为,提升医疗服务质量,实现精准管理。
Objective To explore the effect of the disease-based diagnosis and treatment module applied to costs control management in inpatients with diagnosis-related groups(DRG)of malignant hyperplastic diseases undergoing chemotherapy and/or immunotherapy.Methods The case data of medical insurance for urban workers with malignant hyperplastic diseases undergoing chemotherapy and/or immunotherapy before and after the implementation of the disease-based diagnosis and treatment module were collected from our hospital,involving 394 pre-implementation cases and 584 post-implementation cases.An analysis was performed on patients'hospital stay and total medical costs,as well as drugs expenses,expenses for consumables,expenses for laboratory test,examination costs and their proportion changes before and after the implementation of the disease-based diagnosis and treatment module.Results After applying the disease-based diagnosis and treatment module to costs control,patients with DRG of"chemotherapy and/or immunotherapy for malignant hyperplastic diseases"had less total hospitalization costs,hospital stay,drugs expenses and expenses for consumables,lower proportion of drugs expenses,and higher proportion of expenses for laboratory test as compared with those before the implementation(all P<0.05);there was no statistically significant difference between examination costs,expenses for laboratory test,proportion of examination costs,or proportion of expenses for consumables before and after the implementation of the disease-based diagnosis and treatment module(all P>0.05).Conclusion Utilization of the disease-based diagnosis and treatment module is feasible and effective in costs control management,which might favor standardizing clinical diagnosis and treatment behaviors,improve medical service quality,and achieve precision management.
作者
古旗
何家礼
沈劲松
GU Qi;HE Jia-li;SHEN Jin-song(Department of Medical Administration,the Second Affiliated Hospital of Guangxi University of Technology and Science,Liuzhou 545006,China)
出处
《广西医学》
CAS
2020年第22期2965-2967,2980,共4页
Guangxi Medical Journal
基金
广西医药卫生科研课题(Z20180141)。
关键词
病种基础诊疗模块
疾病诊断相关分组
控费
恶性增生性疾病
化学治疗
免疫治疗
Disease-based diagnosis and treatment module
Diagnosis-related groups
Costs control
Malignant hyperplastic diseases
Chemotherapy
Immunotherapy
